All In Biotech

Free tool

FAERS Monitor: Maxalt-Mlt

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 020865 or its brand name (Maxalt-Mlt, Rizatriptan Benzoate). Reports on generic versions are filed under their own applications.

Reports

2,429

Serious

1,490

61% of reports

Hospitalization

512

Death reported

55

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • drug ineffective469
  • headache324
  • nausea309
  • migraine274
  • off label use270
  • fatigue198
  • drug intolerance185
  • hypersensitivity184
  • product use in unapproved indication179
  • diarrhoea141
  • pain139
  • vomiting135
  • swelling face134
  • dysphonia133
  • swollen tongue130

Reports by year received

View as table
YearReports
200410
200513
200618
200735
200843
200944
201041
201149
201243
201355
201456
2015121
2016214
2017134
2018153
2019181
2020154
2021126
2022198
2023187
2024203
2025205
2026146

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,051,730 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
swollen tongueSignal13036.230.64,401
migraineSignal27424.922.36,278
dysphoniaSignal13319.716.72,348
swelling faceSignal13417.915.12,117
drug intoleranceSignal18516.614.52,706
hypersensitivitySignal1848.67.51,236
product use in unapproved indicationSignal1796.35.4794
headacheSignal3244.54.0898
nauseaSignal3093.43.0536
drug ineffectiveSignal4693.12.8701
off label useSignal2702.72.4293
vomitingSignal1352.52.1121
fatigueSignal1982.21.9134
pain1392.01.766
diarrhoea1411.91.660

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.